Communication of the meeting of Transparency Council No. 33/2025 on 4 August 2025 with resolutions
We invite you to read minutes of the meeting of Transparency Council No. 33/2025 on 4 August 2025 during which the following resolutions were adopted:
- At its meeting on 4 August 2025, the Transparency Council adopted position No. 102/2025 on the appraisal of drug Staloral 300 (mixtures of allergen extracts) for the following indication: treatment of allergic conditions;
- At its meeting on 4 August 2025, the Transparency Council adopted position No. 103/2025 on the appraisal of drug Pluvicto (lutetium (177Lu) vipivotide tetraxetan) under drug program B.56. “Treatment of patients with prostate cancer (ICD-10: C61)”;
- At its meeting on 4 August 2025, the Transparency Council adopted position No. 104/2025 on the appraisal of drug Oralair extract of allergens from grass pollen indicated for the treatment of allergic rhinitis;
- At its meeting on 4 August 2025, the Transparency Council adopted opinion No. 133/2025 on the draft program “Health policy program in the field of rehabilitation, physical therapy, and physiotherapy for residents of the Kodrąb Municipality for the years 2025-2027”
- At its meeting on 4 August 2025, the Transparency Council adopted opinion No. 134/2025 on the inclusion of medicinal products containing the active substance arsenicum trioxidum in the scope of indications for use or dosage, or method of administration other than those specified in the Summary of Product Characteristics, i.e. acute promyelocytic leukemia;
- At its meeting on 4 August 2025, the Transparency Council adopted opinion No. 135/2025 on the inclusion of medicinal products containing the active substance mycophenolate mofetil in the scope of indications for use or dosage, or method of administration other than those specified in the Summary of Product Characteristics;
- At its meeting on 4 August 2025, the Transparency Council adopted opinion No. 136/2025 on the inclusion of medicinal products containing the active substance sirolimus in the scope of indications for use or dosage, or method of administration other than those specified in the Summary of Product Characteristics, i.e. cytopenia in the course of autoimmune lymphoproliferative syndrome.